British journal of addiction 2012-06-01

Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial.

Carsten Rygaard Hjorthøj, Allan Fohlmann, Anne-Mette Larsen, Mikkel Arendt, Merete Nordentoft

Index: Addiction 107(6) , 1123-31, (2012)

Full Text: HTML

Abstract

To assess correlations and agreement between timeline follow-back (TLFB)-assisted self-report and blood samples for cannabis use.Secondary analysis of a randomized trial.Copenhagen, Denmark.One hundred and three patients from the CapOpus trial with cannabis use disorder and psychosis, providing 239 self-reports of cannabis use and 88 valid blood samples.Delta-9-tetrahydrocannabinol (THC), 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) detected in plasma using high-performance liquid chromatography with tandem mass spectrometry detection. Self-report of cannabis-use last month by TLFB. Pearson's r, sensitivity and specificity calculated as measures of correlation or agreement.Correlations were strong; r = 0.75 for number of days and r = 0.83 for number of standard joints in the preceding month when excluding outliers. Including outliers, coefficients were moderate to strong (r = 0.49). There were differences in subgroups, mainly inconsistent, depending on inclusion or exclusion of outliers. Sensitivity and specificity for TLFB detecting the presence or absence of cannabis use were 95.7% [95% confidence interval (CI) 88.0-99.1%) and 72.2% (95% CI 46.5-90.3%), respectively. Using 19 days as cut-off on TLFB, they were 94.3% (95% CI 86.0-98.4%) and 94.4% (95% CI 72.2-99.9%), respectively. Area under the receiver operating characteristic (ROC) curve was 0.96.Timeline follow-back (TLFB)-assisted self-report of cannabis use correlates highly with plasma-delta-9-tetrahydrocannabinol in patients with comorbid cannabis use disorder and psychosis. Sensitivity and specificity of timeline follow-back appear to be optimized with 19 days as the cut-off point. As such, timeline follow-back may be superior to analysis of blood when going beyond 19 days of recall.© 2011 The Authors, Addiction © 2011 Society for the Study of Addiction.


Related Compounds

Related Articles:

Collision victim travels for "seven kilometres" on top of the car that hit him.

2012-10-01

[J. Forensic Leg. Med. 19(7) , 431-3, (2012)]

Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.

2011-10-01

[Clin. Chem. 57(10) , 1406-14, (2011)]

On-site test for cannabinoids in oral fluid.

2012-10-01

[Clin. Chem. 58(10) , 1418-25, (2012)]

Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

2009-11-01

[Drug Alcohol Depend. 105(1-2) , 24-32, (2009)]

Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis.

2007-10-01

[J. Anal. Toxicol. 31(8) , 477-85, (2007)]

More Articles...